Event on

View expert presentations on point-of-care testing for diabetes and in the context of COVID-19

Learning Objectives

Diabetes patients are more likely to experience severe complications and higher mortality if they contract COVID-19, especially those with poorly managed diabetes. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13]

  • Point-of-care testing for HbA1c aids in achieving improved glycemic control with just one single office visit. [11] [12] [13]
  • Despite the viral origin of COVID-19, a standard reflex by physicians is to start treatment with antibiotics since cough, fever, and radiologic infiltrates are hallmarks of bacterial community-acquired pneumonia which requires antibiotic treatment. [14]
  • The detection of CRP is of certain value to distinguish whether there is bacterial infection in the lung. [15]
  • CRP may reflect disease severity and may be an independent predictor of adverse outcome in COVID-19 patients. [16] [17] [18] [19] [20]
  • Antibiotics should be reserved for the patients with the most severe presentations. [14]
  • Avoid blind or inappropriate use of antibacterial drugs, especially the combination of broad-spectrum antibacterial drugs. [15]

Los puntos de vista y opiniones presentados son solo de los autores. El contenido de este webcast está destinado únicamente a fines informativos/educativos.


  • Susanne Emmerich, Dr. rer. nat. (Ph.D.)

    Susanne Emmerich, Dr. rer. nat. (Ph.D.)

    Diabetes Management in the age of COVID-19 and the value of HbA1c Point of Care Testing


    Dr. Susanne Emmerich has worked in the medical diagnostic industry since 2003, working across various functional responsibilities within the point-of-care diagnostics arena, in the fields of cardiology, diabetes, respiratory and anticoagulation. Since 2013 she works as Medical Affairs Director at Abbott Rapid Diagnostics, formerly Alere. In 2002 she obtained the Dr. rer nat. degree in Biology at the Heinrich-Heine-University Düsseldorf.

  • Dr Carl Llor

    Dr Carl Llor

    C-Reactive Protein (CRP) in the context of COVID-19 and CRP as an aid to reduce antibiotic prescribing in respiratory infections


    Dr. Carl Llor’s clinical practice has spanned twenty-two years as a general practitioner within primary care settings. In 1996, he obtained a Ph.D. degree at the University of Rovira i Virgili (URV). In 1993, he was appointed Associate Professor of the Department of General Pathology at URV. He is a member of the General Practitioners Respiratory Infection Network (WONCA). Dr. Llor has been the recipient of several large research projects on respiratory tract infections in primary care. He has published many papers in peer-reviewed journals, mainly on respiratory tract infections and the usage of antibiotics in primary care and delivered numerous lectures during congresses of scientific organisations in the field of general practice, infectious diseases and lung diseases.

Los puntos de vista y opiniones presentados son solo de los autores. El contenido de este webcast está destinado únicamente a fines informativos/educativos.

  1. CDC COVID-19 Response Team. Morbidity and Mortality Weekly Report April 3, 2020; 69(13):382-386. https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm
  2. Richardson S. Hirsch JS, Narasimhan M et. al. JAMA. 2020; 323(20):2052-2059.
  3. Bode B, Garrett V, Messler J et. al. J Diabetes Sci Technol. 2020; 9 May. Online ahead of print.
  4. Palmieri L, Andrianou X, Barbariol P et al. COVID-19 Surveillance Group. Report based on available data on April 20th, 2020. EpiCentro. Accessed 5 June, 2020. https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_20_April_2020.pdf
  5. Chen Y, Yang D, Cheng B. Diabetes Care. 2020; May 14. Online ahead of print.
  6. Guan W, Ni Z, Hu Y et. al. New Engl J Med. 2020;382:1708-20
  7. Zhu L, She Z-G, Chen X et al. Cell Metabolism. 2020 ; 31 :1068-1077
  8. Holman N, Knighton P, Kar P et. al. NHS England. 2020 May 19. Accessed 8 June, 2020. https://www.england.nhs.uk/wp-content/uploads/2020/05/Valabhji-COVID-19-and-Diabetes-Paper-2-Full-Manuscript.pdf
  9. The OpenSAFELY Collaborative. medRxiv preprint posted 07-05-2020. Accessed 8 June, 2020. https://www.medrxiv.org/content/10.1101/2020.05.06.20092999v1.full.pdf
  10. Lian J, Liang Y. Curr Med Res & Op. 2014; 30(11):2233-2240.
  11. Egbunike V, Gerard S. Diabetes Educator. 2013; 39(1):66-73.
  12. Lee-Lewandrowski L, Yeh S, Baron J, Crocker JB, Lewandrowski K. Clin Chim Acta. 2017; 473:71-74.
  13. Crocker JB, Lee-Lewandrowski E, Lewandrowski N, Baron J, Gregory K, Lewandrowski K. AJCP. 2014; 142:640-646.
  14. Jin YH et al. Position article and guideline. Military Medical Research (2020) 7:4; https://doi.org/10.1186/s40779-020-0233-6
  15. Huttner B et al. Clinical Microbiology and Infection 2020; https://doi.org/10.1016/j.cmi.2020.04.024
  16. CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). 3. April 2020; https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidancemanagement-patients.html#lab-findings
  17. Luo X et al. medRxiv preprint 2020; https://doi.org/10.1101/2020.03.21.20040360
  18. Tan C et al. ORCID iD: 0000-0002-2522-4524
  19. Wang L. Médecine et maladies infectieuses 2020; https://doi.org/10.1016/j.medmal.2020.03.007
  20. Li H et al. Journal of Infection 2020; Pre-Proof; https://doi.org/10.1016/j.jinf.2020.03.035

© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. Products available in select markets only. 10005864-01 & 10005865-01